. 2021 Jul 24;12(7):544–556. doi: 10.5306/wjco.v12.i7.544
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Figure 3.
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.